Literature DB >> 20029422

Leukaemogenesis: more than mutant genes.

Jianjun Chen1, Olatoyosi Odenike, Janet D Rowley.   

Abstract

Acute leukaemias are characterized by recurring chromosomal aberrations and gene mutations that are crucial to disease pathogenesis. It is now evident that epigenetic modifications, including DNA methylation and histone modifications, substantially contribute to the phenotype of leukaemia cells. An additional layer of epigenetic complexity is the pathogenetic role of microRNAs in leukaemias, and their key role in the transcriptional regulation of tumour suppressor genes and oncogenes. The genetic heterogeneity of acute leukaemias poses therapeutic challenges, but pharmacological agents that target components of the epigenetic machinery are promising as a component of the therapeutic arsenal for this group of diseases.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20029422      PMCID： PMC2972637          DOI： 10.1038/nrc2765

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  198 in total

Review 1.  Gene silencing in cancer in association with promoter hypermethylation.

Authors:  James G Herman; Stephen B Baylin
Journal:  N Engl J Med       Date:  2003-11-20       Impact factor: 91.245

Review 2.  MicroRNAs: genomics, biogenesis, mechanism, and function.

Authors:  David P Bartel
Journal:  Cell       Date:  2004-01-23       Impact factor: 41.582

Review 3.  The history of cancer epigenetics.

Authors:  Andrew P Feinberg; Benjamin Tycko
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

4.  MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP.

Authors:  Kenji Deguchi; Paul M Ayton; Melina Carapeti; Jeffery L Kutok; Cynthia S Snyder; Ifor R Williams; Nicholas C P Cross; Christopher K Glass; Michael L Cleary; D Gary Gilliland
Journal:  Cancer Cell       Date:  2003-03       Impact factor: 31.743

5.  Depsipeptide (FR 901228) promotes histone acetylation, gene transcription, apoptosis and its activity is enhanced by DNA methyltransferase inhibitors in AML1/ETO-positive leukemic cells.

Authors:  M I Klisovic; E A Maghraby; M R Parthun; M Guimond; A R Sklenar; S P Whitman; K K Chan; T Murphy; J Anon; K J Archer; L J Rush; C Plass; M R Grever; J C Byrd; G Marcucci
Journal:  Leukemia       Date:  2003-02       Impact factor: 11.528

6.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia.

Authors:  M E Huang; Y C Ye; S R Chen; J R Chai; J X Lu; L Zhoa; L J Gu; Z Y Wang
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

7.  Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells.

Authors:  R Taub; I Kirsch; C Morton; G Lenoir; D Swan; S Tronick; S Aaronson; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

8.  Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22.

Authors:  J Groffen; J R Stephenson; N Heisterkamp; A de Klein; C R Bartram; G Grosveld
Journal:  Cell       Date:  1984-01       Impact factor: 41.582

9.  Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia.

Authors:  N Heisterkamp; J R Stephenson; J Groffen; P F Hansen; A de Klein; C R Bartram; G Grosveld
Journal:  Nature       Date:  1983 Nov 17-23       Impact factor: 49.962

10.  Butyrates, as a single drug, induce histone acetylation and granulocytic maturation: possible selectivity on core binding factor-acute myeloid leukemia blasts.

Authors:  Antonella Gozzini; Elisabetta Rovida; Persio Dello Sbarba; Sara Galimberti; Valeria Santini; Sara Galimbert
Journal:  Cancer Res       Date:  2003-12-15       Impact factor: 12.701
View more
  115 in total

1.  Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML.

Authors:  Zejuan Li; Hao Huang; Yuanyuan Li; Xi Jiang; Ping Chen; Stephen Arnovitz; Michael D Radmacher; Kati Maharry; Abdel Elkahloun; Xinan Yang; Chunjiang He; Miao He; Zhiyu Zhang; Konstanze Dohner; Mary Beth Neilly; Colles Price; Yves A Lussier; Yanming Zhang; Richard A Larson; Michelle M Le Beau; Michael A Caligiuri; Lars Bullinger; Peter J M Valk; Ruud Delwel; Bob Lowenberg; Paul P Liu; Guido Marcucci; Clara D Bloomfield; Janet D Rowley; Jianjun Chen
Journal:  Blood       Date:  2012-01-17       Impact factor: 22.113

2.  Loss of promoter methylation contributes to the expression of functionally impaired PRDM1β isoform in diffuse large B-cell lymphoma.

Authors:  Yi-Wen Zhang; Hong-Qiang Xie; Yu Chen; Bo Jiao; Zhi-Xiang Shen; Sai-Juan Chen; Wei-Li Zhao
Journal:  Int J Hematol       Date:  2010-09-22       Impact factor: 2.490

3.  Comprehensive microRNA expression profiling of the hematopoietic hierarchy.

Authors:  O I Petriv; F Kuchenbauer; A D Delaney; V Lecault; A White; D Kent; L Marmolejo; M Heuser; T Berg; M Copley; J Ruschmann; S Sekulovic; C Benz; E Kuroda; V Ho; F Antignano; T Halim; V Giambra; G Krystal; C J F Takei; A P Weng; J Piret; C Eaves; M A Marra; R K Humphries; C L Hansen
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-11       Impact factor: 11.205

4.  Diagnostic usefulness of genomic breakpoint analysis of various gene rearrangements in acute leukemias: a perspective of long distance- or long distance inverse-PCR-based approaches.

Authors:  John Jeongseok Yang; Rolf Marschalek; Claus Meyer; Tae Sung Park
Journal:  Ann Lab Med       Date:  2012-06-20       Impact factor: 3.464

5.  Reduced miR-215 expression predicts poor prognosis in patients with acute myeloid leukemia.

Authors:  Yu-Xin Wang; Ting-Juan Zhang; Dong-Qin Yang; Dong-Ming Yao; Lei Yang; Jing-Dong Zhou; Zhao-Qun Deng; Ji-Chun Ma; Hong Guo; Xiang-Mei Wen; Jiang Lin; Jun Qian
Journal:  Jpn J Clin Oncol       Date:  2016-01-21       Impact factor: 3.019

6.  Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity.

Authors:  Yinfei Tan; Eleonora Sementino; Jonathan Chernoff; Joseph R Testa
Journal:  Am J Cancer Res       Date:  2017-08-01       Impact factor: 6.166

7.  A phase I and pharmacodynamic study of the histone deacetylase inhibitor belinostat plus azacitidine in advanced myeloid neoplasia.

Authors:  Olatoyosi Odenike; Anna Halpern; Lucy A Godley; Jozef Madzo; Theodore Karrison; Margaret Green; Noreen Fulton; Ryan J Mattison; Karen W L Yee; Meghan Bennett; Gregory Koval; Gregory Malnassy; Richard A Larson; Mark J Ratain; Wendy Stock
Journal:  Invest New Drugs       Date:  2014-12-09       Impact factor: 3.850

8.  Transient resistance to DNA damaging agents is associated with expression of microRNAs-135b and -196b in human leukemia cell lines.

Authors:  Tsui-Ting Ho; Xiaolong He; Yin-Yuan Mo; William T Beck
Journal:  Int J Biochem Mol Biol       Date:  2016-08-05

9.  High mobility group A1 protein acts as a new target of Notch1 signaling and regulates cell proliferation in T leukemia cells.

Authors:  Yang Xi; Yu-Sang Li; He-Bin Tang
Journal:  Mol Cell Biochem       Date:  2012-11-16       Impact factor: 3.396

Review 10.  Targeting deregulated epigenetic control in cancer.

Authors:  Sayyed K Zaidi; Andre J Van Wijnen; Jane B Lian; Janet L Stein; Gary S Stein
Journal:  J Cell Physiol       Date:  2013-11       Impact factor: 6.384
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.